Clinical applications for change-point analysis of herpes zoster pain

被引:70
作者
Desmond, RA
Weiss, HL
Arani, RB
Soong, S
Wood, MJ
Fiddian, PA
Gnann, JW
Whitley, RJ
机构
[1] Univ Alabama, Ctr Comprehens Canc, Biostat Unit, Dept Med,Med Stat Sect, Birmingham, AL 35294 USA
[2] Janssen Res Fdn, Titusville, NJ USA
[3] Birmingham Heartlands Hosp, Dept Infect, Birmingham B9 5ST, W Midlands, England
[4] Birmingham Heartlands Hosp, Dept Trop Med, Birmingham B9 5ST, W Midlands, England
[5] Univ Alabama, Childrens Hosp, Dept Pediat, Birmingham, AL 35294 USA
关键词
herpes zoster; bootstrap; piece-wise exponential distribution; survival analysis;
D O I
10.1016/S0885-3924(02)00393-7
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
Pain is the most frequent and disabling complication of herpes zoster: The analysis of pain severity data is complicated by of resolution. Further; three distinct phases characterize pain and chronic. Using two clinical trial datasets as the bases for analyses, the rates of baseline pain resolution were computed across each of three phases and compared for age, severity of pain at onset, and number of lesions at baseline. The results defined transition points of 24.4 +/- 3.34 for the subacute phase and 110.3 +/- 11.9 days for the chronic phase. The model demonstrated a treatment effect of valiciclovir (VACV) during the subacute phase as compared to acyclovir (ACV) (P = 0. 006) and supports effects of age, baseline pain and number lesions on pain cessation rates in the acute phase phase. This model verifies three phases of zoster pain and delineates the impact of treatment and other factors on, the phase-specific rates of pain cessation. (C) U. S. Cancer Pain Relief Committee, 2002.
引用
收藏
页码:510 / 516
页数:7
相关论文
共 11 条
[1]  
Arani RB, 2001, STAT MED, V20, P2429, DOI 10.1002/sim.851
[2]   VALACICLOVIR COMPARED WITH ACYCLOVIR FOR IMPROVED THERAPY FOR HERPES-ZOSTER IN IMMUNOCOMPETENT ADULTS [J].
BEUTNER, KR ;
FRIEDMAN, DJ ;
FORSZPANIAK, C ;
ANDERSEN, PL ;
WOOD, MJ .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1995, 39 (07) :1546-1553
[3]   The effects of pre-emptive treatment of postherpetic neuralgia with amitriptyline: A randomized, double-blind, placebo-controlled trial [J].
Bowsher, D .
JOURNAL OF PAIN AND SYMPTOM MANAGEMENT, 1997, 13 (06) :327-331
[4]   Factors influencing pain outcome in herpes zoster: an observational study with valaciclovir [J].
Decroix, J ;
Partsch, H ;
Gonzalez, R ;
Mobacken, H ;
Goh, CL ;
Walsh, JB ;
Shukla, S ;
Naisbett, B .
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2000, 14 (01) :23-33
[5]   PROPOSED CLASSIFICATION OF HERPES-ZOSTER PAIN [J].
DWORKIN, RH ;
PORTENOY, RK .
LANCET, 1994, 343 (8913) :1648-1648
[6]   Pain and its persistence in herpes zoster [J].
Dworkin, RH ;
Portenoy, RK .
PAIN, 1996, 67 (2-3) :241-251
[7]   Postherpetic neuralgia pathogenesis, treatment, and prevention [J].
Kost, RG ;
Straus, SE .
NEW ENGLAND JOURNAL OF MEDICINE, 1996, 335 (01) :32-42
[8]   ACUTE HERPETIC AND POSTHERPETIC NEURALGIA - CLINICAL REVIEW AND CURRENT MANAGEMENT [J].
PORTENOY, RK ;
DUMA, C ;
FOLEY, KM .
ANNALS OF NEUROLOGY, 1986, 20 (06) :651-664
[9]   POSTHERPETIC NEURALGIA - FURTHER POSTMORTEM STUDIES OF CASES WITH AND WITHOUT PAIN [J].
WATSON, CPN ;
DECK, JH ;
MORSHEAD, C ;
VANDERKOOY, D ;
EVANS, RJ .
PAIN, 1991, 44 (02) :105-117
[10]   How should we measure pain in herpes zoster? [J].
Wood, MJ .
NEUROLOGY, 1995, 45 (12) :S61-S62